This is evident by the clinical success of poly(adenosine 5′-diphosphate–ribose) polymerase inhibition in breast cancer type 1/2 susceptibility (BRCA1/2)-altered prostate cancers and the exceptional response to checkpoint inhibitors in MSH (MutS Homolog)–altered prostate cancers (24, 25). This evidence concerns the gene BRCA1 and prostate carcinoma.